C23寡肽辅助治疗减轻失血相关性肺损伤
该研究在C57BL/6小鼠中建立控制性失血导致平均动脉压25±3 mm Hg持续90分钟的失血性休克模型,随后用生理盐水(溶媒)或联合C23(8 mg/kg体重)进行30分钟容量复苏。复苏后4.5小时取材,结果显示C23辅助治疗组血清乳酸脱氢酶和天冬氨酸氨基转移酶分别降低51.3%和52.2%,肺IL-1β、TNF-α、IL-6 mRNA及髓过氧化物酶活性分别降低66.1%、54.4%、69.7%和24.3%,肺组织学评分降低33.9%,Evans蓝标记白蛋白外渗降低36.8%,细胞间黏附分子-1蛋白水平降低40.3%。作者认为C23可改善失血性休克继发的肺部炎症和血管内皮活化,支持开发靶向CIRP的辅助治疗以减轻失血性休克后肺损伤。
要点
- 小鼠失血性休克(平均动脉压25±3 mm Hg持续90分钟)复苏时辅助给予C23 8 mg/kg,可降低血清乳酸脱氢酶51.3%和天冬氨酸氨基转移酶52.2%。
- C23辅助治疗使肺IL-1β、TNF-α、IL-6 mRNA分别降低66.1%、54.4%、69.7%,髓过氧化物酶活性降低24.3%。
- C23辅助治疗使肺组织学评分降低33.9%,Evans蓝标记白蛋白外渗降低36.8%,细胞间黏附分子-1蛋白降低40.3%。
- 作者认为C23可改善失血性休克继发的肺部炎症和血管内皮活化,支持开发靶向CIRP的辅助治疗。
适用人群与场景
- C57BL/6小鼠,接受控制性失血导致平均动脉压25±3 mm Hg持续90分钟的失血性休克模型。
处置流程与药物剂量
- 失血性休克小鼠在90分钟失血后,用生理盐水(溶媒)或生理盐水加C23(8 mg/kg体重)进行30分钟容量复苏。
- 复苏后4.5小时采集血液和肺组织进行检测。
研究设计与关键结果
- 研究类型为动物实验;C57BL/6小鼠失血性休克模型,比较生理盐水复苏联合C23(8 mg/kg)与单纯生理盐水复苏。
- 血清乳酸脱氢酶和天冬氨酸氨基转移酶在单纯溶媒复苏的失血小鼠中显著升高,C23辅助治疗组分别降低51.3%和52.2%。
- 肺IL-1β、TNF-α、IL-6 mRNA水平及髓过氧化物酶活性在失血性休克后升高,C23治疗组分别降低66.1%、54.4%、69.7%和24.3%。
- C23辅助治疗使肺组织学评分降低33.9%,Evans蓝标记白蛋白肺外渗降低36.8%,细胞间黏附分子-1蛋白水平降低40.3%。
证据类型、等级与局限
- 证据类型:动物实验(小鼠失血性休克模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为C23辅助治疗可改善失血性休克继发的肺部炎症和血管内皮活化,支持开发靶向CIRP的辅助治疗以减轻失血性休克后肺损伤。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Hemorrhagic shock (HS) is an important cause of mortality. HS is associated with an elevated incidence of acute lung injury and acute respiratory distress syndrome, significantly contributing to HS morbidity and mortality. Cold-inducible RNA-binding protein (CIRP) is released into the circulation during HS and can cause lung injury. C23 is a CIRP-derived oligopeptide that binds with high affinity to the CIRP receptor and inhibits CIRP-induced phagocyte secretion of TNF-α. This study was designed to determine whether C23 is able to attenuate HS-associated lung injury.
METHODS: C57BL/6 mice were subjected to controlled hemorrhage leading to a mean arterial pressure of 25 ± 3 mm Hg for 90 minutes. Mice were then volume-resuscitated for 30 minutes with normal saline solution alone (vehicle) or plus adjuvant treatment with C23 (8 mg/kg BW). At 4.5 hours after resuscitation, the blood and lungs were harvested.
RESULTS: Serum levels of organ injury markers lactate dehydrogenase, aspartate aminotransferase were significantly elevated in hemorrhaged mice receiving vehicle and were reduced by 51.3% and 52.2% in mice adjuvantly treated with C23, respectively. Similarly, lung mRNA levels of IL-1β, TNF-α, and IL-6, and lung myeloperoxidase activity were elevated after HS and reduced by 66.1%, 54.4%, 69.7%, and 24.3%, respectively, in mice treated with C23. Adjuvant treatment with C23 also decreased the lung histology score by 33.9%, lung extravasation of albumin carrying Evans blue dye by 36.8%, and the protein level of intercellular adhesion molecule-1, and indicator of vascular endothelial cell activation, by 40.3%.
CONCLUSION: Together, these results indicate that adjuvant treatment with the CIRP-derived oligopeptide C23 is able to improve lung inflammation and vascular endothelial activation secondary to HS, lending support to the development of CIRP-targeting adjuvant treatments to minimize lung injury after HS.
参考来源
- Zhang F, Yang WL, Brenner M, et al. Attenuation of hemorrhage-associated lung injury by adjuvant treatment with C23, an oligopeptide derived from cold-inducible RNA-binding protein. J Trauma Acute Care Surg. 2017. PMID: 28930962. doi:10.1097/TA.0000000000001566
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。